IVERIC bio, Inc. financial data

Industry
Pharmaceutical Preparations
Location
8 Sylvan Way, Parsippany, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Ophthotech Corp. (to 4/11/2019)

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.52K % +23.2%
Debt-to-equity 23.5 % +160%
Return On Equity -57 % -23.5%
Return On Assets -46.2 % -9.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 138M shares +18.4%
Common Stock, Shares, Outstanding 137M shares +18.3%
Entity Public Float 1.09B USD +100%
Common Stock, Value, Issued 137K USD +18.1%
Weighted Average Number of Shares Outstanding, Basic 137M shares +15.4%
Weighted Average Number of Shares Outstanding, Diluted 137M shares +15.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 137M USD +53.3%
General and Administrative Expense 92.5M USD +176%
Operating Income (Loss) -229M USD -86.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -223M USD -82.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -223M USD -82.3%
Earnings Per Share, Basic -1.77 USD/shares -58%
Earnings Per Share, Diluted -1.77 USD/shares -58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 468M USD +144%
Assets, Current 612M USD +74.2%
Property, Plant and Equipment, Net 1.11M USD +150%
Operating Lease, Right-of-Use Asset 755K USD -41.7%
Other Assets, Noncurrent 0 USD
Assets 613M USD +73.9%
Liabilities, Current 39.4M USD +105%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 136M USD +597%
Accumulated Other Comprehensive Income (Loss), Net of Tax -99K USD +74.9%
Retained Earnings (Accumulated Deficit) -937M USD -31.2%
Stockholders' Equity Attributable to Parent 477M USD +43.2%
Liabilities and Equity 613M USD +73.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.6M USD -34.9%
Net Cash Provided by (Used in) Financing Activities 2.59M USD +24.5%
Net Cash Provided by (Used in) Investing Activities 39.3M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 137M shares +18.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.73M USD +87.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 468M USD +144%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.41M USD
Deferred Tax Assets, Valuation Allowance 269M USD +30.4%
Deferred Tax Assets, Gross 269M USD +30.4%
Operating Lease, Liability 774K USD
Depreciation 70K USD +233%
Payments to Acquire Property, Plant, and Equipment 233K USD +101%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -223M USD -81.5%
Lessee, Operating Lease, Liability, to be Paid 786K USD
Property, Plant and Equipment, Gross 2.08M USD +54.9%
Operating Lease, Liability, Current 774K USD -19%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11K USD -98.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 11K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 6.72M USD 0%
Operating Lease, Payments 1.5M USD +33.3%
Additional Paid in Capital 1.41B USD +35%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 33.2M USD +131%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%